BioSpace: Icosavax Turns VLP Tech to COVID-19 Vaccine, with $16.5 Million in New Financing

Icosovax is turning its virus-like particle (VLP) technology to fight COVID-19. The news accompanies $16.5 million in new funding from the Bill and Melinda Gates Foundation and Open Philanthropy, and the publication of preclinical data in Cell.

BioSpace’s Gail Dutton caught up with Icosavax CEO Adam Simpson to discuss its new vaccine candidate, IVX-411 -- read the interview here.

Recent Posts

See All

Icosavax, Inc.

1616 Eastlake Avenue E. Suite 208 
Seattle, WA 98102

  • White Twitter Icon
  • White Facebook Icon
  • White LinkedIn Icon

© 2020 Icosavax, Inc. All rights reserved.